Summary
EudraCT Number:2022-002190-28
Sponsor's Protocol Code Number:SHP674-201\CL1-95014-001
Clinical Trial Type:Outside EU/EEA
Date on which this record was first entered in the EudraCT database:2022-07-04
Trial results
A. Protocol Information
A.2EudraCT number2022-002190-28
A.3Full title of the trial
A Phase 2 Clinical Study of SHP674 in Patients with Newly Diagnosed, Untreated Acute Lymphoblastic Leukemia
A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
A Clinical Study of SHP674 (Pegaspargase) in Participants With Newly Diagnosed, Untreated Acute Lymphoblastic Leukemia
A.4.1Sponsor's protocol code numberSHP674-201\CL1-95014-001
A.5.2US NCT (ClinicalTrials.gov registry) numberNCT04067518
A.7Trial is part of a Paediatric Investigation Plan No
A.8EMA Decision number of Paediatric Investigation Plan
B. Sponsor Information
B.Sponsor: 1
B.1.1Name of SponsorInstitut de Recherches Internationales Servier (IRIS)
B.1.3.4CountryFrance
B.3.1 and B.3.2Status of the sponsorCommercial
B.4 Source(s) of Monetary or Material Support for the clinical trial:
B.4.1Name of organisation providing supportADIR
B.4.2CountryFrance
B.5 Contact point designated by the sponsor for further information on the trial
B.5.1Name of organisationInstitut de Recherches Internationales Servier
B.5.2Functional name of contact pointClinical Studies Department
B.5.3 Address:
B.5.3.1Street Address50 rue Carnot
B.5.3.2Town/ citySURESNES CEDEX
B.5.3.3Post code92284
B.5.3.4CountryFrance
B.5.5Fax number+33155725412
B.5.6E-mail[email protected]
D. IMP Identification
D.IMP: 1
D.1.2 and D.1.3IMP RoleTest
D.2 Status of the IMP to be used in the clinical trial
D.2.1IMP to be used in the trial has a marketing authorisation Yes
D.2.1.1.1Trade name ONCASPAR
D.2.1.1.2Name of the Marketing Authorisation holderLes Laboratoires Servier
D.2.1.2Country which granted the Marketing AuthorisationEuropean Union
D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
D.2.5.1Orphan drug designation number
D.3 Description of the IMP
D.3.1Product namePegaspargase
D.3.2Product code SHP674 \ S95014
D.3.4Pharmaceutical form Powder for solution for injection
D.3.4.1Specific paediatric formulation No
D.3.7Routes of administration for this IMPIntravenous use
D.3.11 The IMP contains an:
D.3.11.1Active substance of chemical origin No
D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
The IMP is a:
D.3.11.3Advanced Therapy IMP (ATIMP) No
D.3.11.3.1Somatic cell therapy medicinal product No
D.3.11.3.2Gene therapy medical product No
D.3.11.3.3Tissue Engineered Product No
D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
D.3.11.5Radiopharmaceutical medicinal product No
D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
D.3.11.7Plasma derived medicinal product No
D.3.11.8Extractive medicinal product No
D.3.11.9Recombinant medicinal product No
D.3.11.10Medicinal product containing genetically modified organisms No
D.3.11.11Herbal medicinal product No
D.3.11.12Homeopathic medicinal product No
D.3.11.13Another type of medicinal product No
D.8 Information on Placebo
E. General Information on the Trial
E.1 Medical condition or disease under investigation
E.1.1Medical condition(s) being investigated
Acute Lymphoblastic Leukemia
E.1.1.1Medical condition in easily understood language
Acute Lymphoblastic Leukemia
E.1.1.2Therapeutic area Diseases [C] - Cancer [C04]
MedDRA Classification
E.1.2 Medical condition or disease under investigation
E.1.2Version 21.0
E.1.2Level LLT
E.1.2Classification code 10000845
E.1.2Term Acute lymphoblastic leukemia
E.1.2System Organ Class 100000004864
E.1.3Condition being studied is a rare disease No
E.2 Objective of the trial
E.2.1Main objective of the trial
Phase 1:
To assess the safety and tolerability of a single dose of SHP674 in Japanese participants (dose confirmation) in the tolerability assessment period of Part 1.

Phase 2:
To assess the safety, pharmacokinetics and efficacy of SHP674 dose in Part 2 (found to be tolerated in Part 1) in the treatment of newly diagnosed untreated acute lymphoblastic leukemia (ALL) in Japanese participants.
E.2.2Secondary objectives of the trial
Part 1:
– To assess the percentage of subjects with newly diagnosed,untreated ALL who have a plasma asparaginase activity of ≥0.1 IU/mL 14 days (336 hours) after the first dose of SHP674.
– To assess the safety of SHP674.
– To assess the PK of SHP674.
– To assess the immunogenicity of SHP674.
– To assess the survival rate at 1 year after the start of study treatment.
– To assess the event-free survival rate at 1 year after the start of study treatment.
Part 2:
– To assess the safety of SHP674
– To assess the PK of SHP674.
– To assess the immunogenicity of SHP674.
– To assess the survival rate at 1 year after the start of study treatment.
– To assess the event-free survival rate at 1 year after the start of study treatment
E.2.3Trial contains a sub-study No
E.3Principal inclusion criteria
• Age 1 to ≤21 years at the time of informed consent;
• Eastern Cooperative Oncology Group performance status (ECOG PS) 0 to 2;
• Newly diagnosed, untreated precursor B-cell ALL
• No prior therapy for malignant tumor such as chemotherapy and radiation therapy before signing the informed consent;
• Life expectancy of at least 6 months from the date of enrollment;
E.4Principal exclusion criteria
• Mature B-cell ALL ; Philadelphia chromosome-positive (Ph+) or BCR-ABL1-positive ALL
• Preexisting known coagulopathy ;
• History of pancreatitis;
• Continuous use of corticosteroids;
• Prior treatment or possible prior treatment with an L-asparaginase preparation;
• History of sensitivity to polyethylene glycol (PEG) or PEG-based drugs;
• Pregnant
E.5 End points
E.5.1Primary end point(s)
Part 1:
–Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) and SHP-674-Related TEAEs During the Tolerability Assessment Period

Part 2:
–Percentage of Participants Who Achieved a Plasma Asparaginase Activity of ≥0.1 International Units Per Milliliter (IU/mL) 14 Days (336 Hours) After the First Dose of SHP674
E.5.1.1Timepoint(s) of evaluation of this end point
Part 1:
– Incidence of TEAEs and Drug-related TEAEs: Enrollment up to 5 weeks
Part 2:
–Plasma asparaginase activity :14 days after the first dose of SHP674
E.5.2Secondary end point(s)
–Incidence and Nature of TEAEs and Drug-related TEAEs.
–Parts 1 and 2: Percentage of Participants With Anti-Drug (SHP674) Antibody (ADA) and Anti-Polyethylene Glycol (PEG) Antibody.
–Part 1: Percentage of Participants Who Achieved a Plasma Asparaginase Activity of ≥0.1 IU/mL 14 Days (336 Hours) After the First Dose of SHP674.
–Part 2: Percentage of Participants With Plasma Asparaginase Activity of ≥0.1 IU/mL or <0.1 IU/mL.
–Survival Rate at 1 Year After the Start of Study Treatment.
–Event-free Survival Rate at 1 Year After the Start of Study Treatment.
E.5.2.1Timepoint(s) of evaluation of this end point
• Incidence of TEAEs and Drug-related TEAEs: Part 1 and 2: Up to 1 year
• Laboratory values, Vital signs, PK parameters, Survival rate, and Event-free survival rate at 1 year after the start of study treatment
• Percentage of Participants With Anti-Drug (SHP674) Antibody (ADA) and Anti-Polyethylene Glycol (PEG) Antibody : Part 1: Predose and 25 days post dose; Part 2: Predose and 25 days post dose
• Plasma asparaginase activity :Part 1:14 days after the first dose of SHP674; Part 2: Day 1 (pre-dose, 5 min, 4 hours, 24 hours post dose), Days 2, 4, 11, 14, 18, 25 post dose
E.6 and E.7 Scope of the trial
E.6Scope of the trial
E.6.1Diagnosis No
E.6.2Prophylaxis No
E.6.3Therapy No
E.6.4Safety Yes
E.6.5Efficacy Yes
E.6.6Pharmacokinetic Yes
E.6.7Pharmacodynamic No
E.6.8Bioequivalence No
E.6.9Dose response No
E.6.10Pharmacogenetic No
E.6.11Pharmacogenomic No
E.6.12Pharmacoeconomic No
E.6.13Others No
E.7Trial type and phase
E.7.1Human pharmacology (Phase I) No
E.7.1.1First administration to humans No
E.7.1.2Bioequivalence study No
E.7.1.3Other No
E.7.1.3.1Other trial type description
E.7.2Therapeutic exploratory (Phase II) Yes
E.7.3Therapeutic confirmatory (Phase III) No
E.7.4Therapeutic use (Phase IV) No
E.8 Design of the trial
E.8.1Controlled No
E.8.1.1Randomised No
E.8.1.2Open Yes
E.8.1.3Single blind No
E.8.1.4Double blind No
E.8.1.5Parallel group No
E.8.1.6Cross over No
E.8.1.7Other No
E.8.2 Comparator of controlled trial
E.8.2.1Other medicinal product(s) No
E.8.2.2Placebo No
E.8.2.3Other No
E.8.2.4Number of treatment arms in the trial1
E.8.3 Will this trial be conducted at a single site globally? No
E.8.4 Will this trial be conducted at multiple sites globally? Yes
E.8.6 Trial involving sites outside the EEA
E.8.6.2Trial being conducted completely outside of the EEA Yes
E.8.6.3Specify the countries outside of the EEA in which trial sites are planned
Japan
E.8.7Trial has a data monitoring committee No
E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
End of Trial is defined as the last visit of the last subject
E.8.9 Initial estimate of the duration of the trial
E.8.9.2In all countries concerned by the trial years2
E.8.9.2In all countries concerned by the trial months4
F. Population of Trial Subjects
F.1 Age Range
F.1.1Trial has subjects under 18 Yes
F.1.1Number of subjects for this age range: 26
F.1.1.1In Utero No
F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
F.1.1.3Newborns (0-27 days) No
F.1.1.4Infants and toddlers (28 days-23 months) Yes
F.1.1.4.1Number of subjects for this age range: 1
F.1.1.5Children (2-11years) Yes
F.1.1.5.1Number of subjects for this age range: 19
F.1.1.6Adolescents (12-17 years) Yes
F.1.1.6.1Number of subjects for this age range: 6
F.1.2Adults (18-64 years) No
F.1.3Elderly (>=65 years) No
F.2 Gender
F.2.1Female Yes
F.2.2Male Yes
F.3 Group of trial subjects
F.3.1Healthy volunteers No
F.3.2Patients Yes
F.3.3Specific vulnerable populations No
F.3.3.1Women of childbearing potential not using contraception No
F.3.3.2Women of child-bearing potential using contraception No
F.3.3.3Pregnant women No
F.3.3.4Nursing women No
F.3.3.5Emergency situation No
F.3.3.6Subjects incapable of giving consent personally No
F.3.3.7Others No
F.4 Planned number of subjects to be included
F.4.2 For a multinational trial
F.4.2.2In the whole clinical trial 26
F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
None
G. Investigator Networks to be involved in the Trial
H.4 Third Country in which the Trial was first authorised
H.4.1Third Country in which the trial was first authorised: Japan